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Summary Breast cancer in men is rare and is clearly due in some cases to an inherited predisposition. A total of 28 male breast cancer
patients were tested for BRCA2 mutations; two frameshifts and one putative missense mutation were identified. One of the frameshifts was
detected in the same position as a mutation estimated to be responsible for 40% of all male breast cancer cases in Iceland.
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It is estimated that 5-10% offemale breast cancer cases are due to
inheritance of autosomal dominant susceptibility genes (Claus et
al, 1991). Two such genes, BRCAJ and BRCA2, localized to 17q
and 13ql2-13 respectively, have recently been identified (Miki et
al, 1994; Wooster et al, 1995). Germline mutations in either ofthe
two genes confers an 80-90% lifetime risk of breast cancer in
women and an increased risk of ovarian cancer (Wooster et al,
1994). BRCAJ is estimated to account for approximately one-half
of all highly penetrant dominant breast cancer families and the
majority offamilies with cases offemale breast and ovarian cancer
(Easton et al, 1993) but, according to both linkage and mutation
studies, does not account for a significant proportion of families
with cases of male breast cancer (Stratton et al, 1994; Strewing
et al, 1995a). Unlike BRCAJ, a considerable number of BRCA2
mutations have been reported in heritable cases of male breast
cancer (Wooster et al, 1995; Couch et al, 1996; Phelan et al, 1996;
Tavtigian et al, 1996; Thorlacius etal, 1996; Friedman et al, 1997).
To determine the frequency of BRCA2 germline mutations in
men with breast cancer, we have screened DNA from 26 affected
men plus two women with early-onset breast cancer who had an
affected male relative.
MATERIALS AND METHODS
DNA samples
Blood samples were drawn from breastcancer-affected individuals
from a case-control study of male breast cancer conducted in the
Yorkshire Trent and North-West regions of the UK. Genomic
DNA was extracted from blood using standard procedures. DNA
samples were available from 26 male patients and two affected
female patients who had male relatives with breast cancer.
BRCA1 185delAG mutation screen
The DNA samples were tested for the 185delAG mutation in the
BRCAJ gene by polymerase chain reaction (PCR) amplification.
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PCR fragments were run on a 6% non-denaturing acrylamide
gel and visualized by UV transillumination following ethidium
bromide staining.
Polymerase chain reaction (PCR), single - strand
conformation polymorphism (SSCP) analysis and
sequence analysis
PCR amplification of 200 to 300-bp DNA fragments covering the
entire BRCA2 coding region was performed with a set of 62 pairs
ofprimers designed by DrRichard Wooster (personal communica-
tion; primer sequences available on request). Six ofthe 62 BRCA2
PCR products from each individual were pooled and run on
0.5 x MDE (Flowgen) gels in 0.6 x TBE. After electrophoresis,
fragments were transferred to a nylon membrane (HybondN+,
Amersham) and hybridized with radioactively end-labelled PCR
primers. After hybridization, SSCP conformers were detected by
autoradiography. All variant products identified were reamplified
from genomic DNA, and sequenced using a 377 DNA sequencer
(Applied Biosystems).
RESULTS
Before BRCA2 screening, all 28 individuals were tested for
185delAG in BRCAI, as this mutation has been identified in three
breast and breast/ovarian cancer families from the same geograph-
ical area (northem England). It should be noted that, although this
mutation is common in Ashkenazi Jews (Struewing et al, 1995b),
haplotype analysis suggests that none of the three families
mentioned here are of Ashkenazi Jewish descent (D Kelsell,
personal communication). All individuals in this study were found
to be negative for this deletion (data not shown) and subsequently
were screened for BRCA2 mutations. BRCA2 consists of 26 exons
spanning 10 254 bp (Tavtigian et al, 1996). Three mutations were
detected (Figure 1). DNA from individual MB1 has a single A
insertion in a run of seven As in exon 24. In individual MB2,
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Figure 1 Germline BRCA2 mutations in breast cancer-affected men. SSCP profiles are shown on the left, with band shifts due to the mutant alleles arrowed.
Two normal profiles are shown in each case for comparison. Corresponding sequence electropherogram traces are shown on the right. Individuals MB1 and
MB2 have frame-shift mutations due to an 'A' insertion and an 'AA' deletion respectively. Individual MB3 has an A-_G transition.
a 2-bp amino acid deletion was detected in exon 9. These muta-
tions cause frameshifts predicted to result in premature termina-
tion of translation. A putative missense mutation was detected in
DNA from individual MB3. This consists of an A-_G transition in
codon 2247 of exon 11 causing the amino acid substitution serine
to glycine. The functional significance ofthis amino acidchange is
unknown. To determine if this variant is simply a common poly-
morphism, 34 further individuals were tested for this transition by
SSCP analysis and no positives were identified. None of these
three BRCA2 mutations had previously been reported (Wooster et
al, 1995; Couch et al, 1996; Foster et al, 1996; Goggins et al, 1996;
Lancaster et al, 1996; Miki et al, 1996; Neuhausen et al, 1996;
Phelan et al, 1996; Takahashi et al, 1996; Tavtigian et al,
1996; Teng et al, 1996; Thorlacius et al, 1996; Weber et al, 1996;
Gayther et al, 1997; the BIC database). No further frameshift or
missense mutations were identified; however, a polymorphic
SSCP conformer was detected in 12 of the 28 individuals. Direct
sequencing characterized it as a silent A-_G base substitution in
codon 1132 of exon 11. This polymorphism has been reported
previously (Phelan et al, 1996). These sequence variants are
summarized in Table 1.
DISCUSSION
In this study, four variant conformers were identified, one of
which is clearly a polymorphism. Of the remaining alterations
detected, two cause a frameshift predicted to result in a truncated
protein. The third sequence variant, consisting of an A-_G transi-
tion in codon 2247 of exon 11, causes the amino acid substitution
serine to glycine, which is of unknown functional significance.
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Table 1 Germline BRCA2mutations in men with breast cancers
Individual Exon Codon Variant
Mutations MB1 24 3085 insA:TGAAAAAAAACA
MB2 9 258 delAA: AATCAaaGAG
(Putative) MB3 11 2247 AGT(Ser)-_GGT(Gly)
Polymorphism MB4 11 1132 AAA(Lys)-_AAG(Lys)
The presence of this sequence alteration in the tumour of patient
MB3 could not be determined because of the lack of archival
material, and no DNA was available from otherfamily members to
confirm segregation with the disease. Failure to detect this variant
in 34 additional individuals tested strengthens the argument for
a deleterious effect in this breast cancer-affected individual.
However, serine -* glycine is a conservative amino acid change
and the amino acid at this position is poorly conserved between
human and murine BRCA2 sequences (Connor et al, 1997).
Both of the frameshift mutations and the putative missense
mutation identified in this study are novel and occurred in three
different exons (9, 11 and 24) of the BRCA2 gene. However, the
2-bp amino acid deletion detected in patient MB2 has occurred in
the same position of exon 9 as the 999de15 mutation, which
accounts for 40% of all male breast cancer patients in Iceland
(Thorlacius et al, 1996). This suggests that mutations in codon 258
of the BRCA2 gene could be associated with increased suscepti-
bility to male breast cancer.
The 28 breast cancer patients screened for germline BRCA2
mutations were selected without any initial regard for family
history or age at onset. However, information on family history
was available for all ofthe individuals included in this study: four
patients had at least two additional cases of breast cancer in their
families, five individuals had families with a single further case of
breast cancer and one patient had one relative with breast and one
with ovarian cancer. The remaining patients had no reported
family history ofbreast or ovarian cancer. However, these individ-
uals had recorded incidences of other cancers in their families,
including colon, stomach, bladder, cervical and throat cancer.
Some family history is known for the three individuals with
BRCA2 mutations. Individual MB2 developed breast cancer at the
age of 68 and has two male and two female affected relatives.
Patients MB1 and MB3, with an age of incidence of 65 and 64
years respectively, have no known family history of breast or
ovarian cancer. However, other malignancies have been reported
in these two families, including sarcoma, cervical and stomach
cancer. Our data, together with previous reports, suggest that
BRCA2 could be involved in other forms of cancer in addition to
breast cancer (Goggins et al, 1996; Berman et al, 1996; Couch et
al, 1996; Phelan et al, 1996; Thorlacius et al, 1996). To investigate
this possibility, mutation analyses on tumour samples from other
malignancies in families with germlime BRCA2 mutations are
required.
The frequency of BRCA2 mutations detected (2 or 3 out of 28,
or 7-11%) is in good agreement with a previous study (Couch
et al, 1996). The low number of mutations identified could be
explained by the existence of non-coding mutations that are not
covered by this approach. Furthermore, some mutations may
remain undetected by SSCP. Although the sensitivity of this
method is high, it depends largely on the electrophoretic condi-
tions, the gel concentration and the size of the DNA fragments
examined (Sheffield et al, 1993; Ravnik-Glavac et al, 1994).
Alternatively, mutations in other genes, acquired either somati-
cally or in the germline, may be responsible for some instances of
male breast cancer. The identification of such genes coupled with
more sensitive mutation detection systems shouldhelp toprovide a
better understanding of the genetic mechanisms underlying breast
cancer.
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